Operationalizing Biosimilars in Specialty Pharmacies

Video content above is prompted by the following:

• What does the current process look like for switching between reference products and biosimilars and between biosimilars at specialty pharmacies, and how can it be streamlined?
• In states that allow pharmacists to switch to a biosimilar without prior prescriber approval, how effective are automatic substitutions based on interchangeability and collaborative practice agreements?